CompletedPhase 2

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

China60 participantsStarted 2021-01-28

Plain-language summary

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosed with macular edema secondary to Branch retinal vein occlusion (BRVO) or Hemiretinal vein occlusion (HRVO) within 12 months
✓. BCVA score between 78 and 19 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/400)
✓. CRT ≥ 250μm
✓. No optometric media opacity and pupil abnormal

What they're measuring

Change from baseline in best-corrected visual acuity (BCVA) at Week 24

Timeframe: Baseline to Week 24

Trial details

NCT IDNCT04667897

SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-07-13

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion trials